



COPY OF PAPERS
ORIGINALLY FILED

PATENT
454313-2280.1

4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Franciscus Antonius Maria RIJSEWIJK et al.
Serial No. : 10/077,489
Filed : February 15, 2002
Title : BOVINE POLYNUCLEOTIDE VACCINE FOR
THE INTRADERMAL ROUTE
Group Art Unit : 1484
Examiner : Not Yet Assigned

745 Fifth Avenue
New York, NY 10151

I hereby certify that this correspondence is being deposited with
the United States Postal Service as first class mail in an envelope
addressed to: Hon. Commissioner of Patents and Trademarks
Washington, DC 20231, on March 21, 2002.

William S. Frommer, Reg. No. 25,506

Name of Applicant, Assignee or Registered Representative

William S. Frommer
Signature
March 21, 2002

Date of Signature

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Supplemental to the Preliminary Amendment filed February 15, 2002, please
amend the application as follows:

IN THE SPECIFICATION:

Please amend the paragraph added to page 1, before line 1, to read as follows:

200523ED 68444001

--This application is a divisional of application U.S. Patent Serial No. 09/232,469, filed January 15, 1999, now allowed, which in turn is a continuation-in-part of copending International Application PCT/FR97/01322 having an international filing date of 16 July 1997, and designating the U.S. and claiming priority from French application Serial No. 96/09402, filed 16 July 1996. All of the above-mentioned applications, as well as documents cited herein and documents referenced or cited in documents cited herein, are hereby incorporated herein by reference. Vectors of vaccines or immunological compositions of documents cited herein or documents referenced in documents cited herein or portions of such vectors (e.g., one or more or all of regulatory sequences such as DNA for promoter, leader for secretion, terminator), may to the extent practicable with respect to the preferred host and administration route of this application, also be employed in the practice of this invention; and, DNA for vectors of vaccines or immunological compositions herein can be obtained from available sources and knowledge in the art, e.g., GeneBank, such that from this disclosure, no undue experimentation is required to make or use such vectors; see also PCT/IB97/01040, filed July 28, 1997 and designating the U.S., incorporated herein by reference. --

REMARKS

The amendment to the specification is made to correct the filing date of the parent application 09/232,469.

Attached hereto is a marked up version of the changes made to the specification by the present amendment. The attached page is entitled "**Version with Markings to Show Changes Made.**"


It is believed that no additional fee is due. If, however, a fee is due, please charge Deposit Account No. 50-0320.

Please issue a corrected Filing Receipt.

An early examination on the merits is respectfully requested.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP
Attorneys for Applicants

By 
William S. Frommer
Registration No. 25,506
(212) 588-0800

20062250 588-0800

APPENDIX SHOWING AMENDMENTS TO THE SPECIFICATION

Please amend the paragraph added to page 1, before line 1, to read as follows:

--This application is a divisional of application U.S. Patent Serial No. 09/232,469, filed [July 15, 1999] January 15, 1999, now allowed, which in turn is a continuation-in-part of copending International Application PCT/FR97/01322 having an international filing date of 16 July 1997, and designating the U.S. and claiming priority from French application Serial No. 96/09402, filed 16 July 1996. All of the above-mentioned applications, as well as documents cited herein and documents referenced or cited in documents cited herein, are hereby incorporated herein by reference. Vectors of vaccines or immunological compositions of documents cited herein or documents referenced in documents cited herein or portions of such vectors (e.g., one or more or all of regulatory sequences such as DNA for promoter, leader for secretion, terminator), may to the extent practicable with respect to the preferred host and administration route of this application, also be employed in the practice of this invention; and, DNA for vectors of vaccines or immunological compositions herein can be obtained from available sources and knowledge in the art, e.g., GeneBank, such that from this disclosure, no undue experimentation is required to make or use such vectors; see also PCT/IB97/01040, filed July 28, 1997 and designating the U.S., incorporated herein by reference. --